Literature DB >> 18838698

High-dose etoposide: from phase I to a component of curative therapy.

Steven N Wolff1, John D Hainsworth, F Anthony Greco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18838698      PMCID： PMC2661465          DOI： 10.1200/JCO.2008.19.0892

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  37 in total

1.  Is total body irradiation a necessary component of preparative therapy for autologous transplantation in non-Hodgkin's lymphoma.

Authors:  R S Stein; J P Greer; S Goodman; S J Brandt; D S Morgan; W R Macon; T L McCurley; S N Wolff
Journal:  Leuk Lymphoma       Date:  2001-03

Review 2.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

3.  Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.

Authors:  R S Stein; J P Greer; S Goodman; S J Brandt; D S Morgan; W R Macon; T L McCurley; S N Wolff
Journal:  Bone Marrow Transplant       Date:  2000-02       Impact factor: 5.483

4.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

Authors:  W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

5.  Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation.

Authors:  H M Lazarus; M R Gottfried; R H Herzig; G L Phillips; R S Weiner; G P Sarna; J Fay; S N Wolff; O Sudilovsky; R P Gale; G P Herzig
Journal:  Cancer       Date:  1982-05-01       Impact factor: 6.860

6.  Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow.

Authors:  G L Phillips; R H Herzig; H M Lazarus; J W Fay; S N Wolff; W B Mill; H Lin; P R Thomas; G P Glasgow; D C Shina
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

7.  High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.

Authors:  S N Wolff; D H Johnson; J D Hainsworth; F A Greco
Journal:  J Clin Oncol       Date:  1984-04       Impact factor: 44.544

8.  High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.

Authors:  S N Wolff; M F Fer; C M McKay; K R Hande; J D Hainsworth; F A Greco
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

9.  Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.

Authors:  Volker Möbus; Hannes Wandt; Norbert Frickhofen; Carmelo Bengala; Kim Champion; Rainer Kimmig; Helmut Ostermann; Axel Hinke; Jonathan A Ledermann
Journal:  J Clin Oncol       Date:  2007-08-13       Impact factor: 44.544

10.  Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.

Authors:  G L Phillips; J W Fay; G P Herzig; R H Herzig; R S Weiner; S N Wolff; H M Lazarus; C Karanes; W E Ross; B S Kramer
Journal:  Cancer       Date:  1983-11-15       Impact factor: 6.860
View more
  1 in total

1.  TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo.

Authors:  Fernando Gómez-Herreros; Rocío Romero-Granados; Zhihong Zeng; Alejandro Alvarez-Quilón; Cristina Quintero; Limei Ju; Lieve Umans; Liesbeth Vermeire; Danny Huylebroeck; Keith W Caldecott; Felipe Cortés-Ledesma
Journal:  PLoS Genet       Date:  2013-03-07       Impact factor: 5.917
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.